CN102526195A - Medicinal composition for treating coronary disease and preparation method thereof - Google Patents
Medicinal composition for treating coronary disease and preparation method thereof Download PDFInfo
- Publication number
- CN102526195A CN102526195A CN2011102470402A CN201110247040A CN102526195A CN 102526195 A CN102526195 A CN 102526195A CN 2011102470402 A CN2011102470402 A CN 2011102470402A CN 201110247040 A CN201110247040 A CN 201110247040A CN 102526195 A CN102526195 A CN 102526195A
- Authority
- CN
- China
- Prior art keywords
- extract
- moschus
- eupolyphaga seu
- seu steleophaga
- styrax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating coronary disease and a preparation method thereof. The medicinal composition is prepared from musk, bezoar, ginseng extracts, cinnamon, storax, borneol, toad venom, ground beetle and auxiliary materials. The medicinal composition has the effects of activating Yang based on aromatic herbs, inducing resuscitation and relieving pains, and tonifying vital energy and strengthening heart, is used for treating angina pectoris, choking sensation in chest and myocardial infarction caused by myocardial ischemia, and can be used in ischemic myocardium collateral revascularization and medicinal bypass of coronary disease.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of treating coronary heart disease and preparation method thereof, belong to field of pharmaceutical technology.
Background technology
Angina pectoris, myocardial infarction are a kind of commonly encountered diseases, frequently-occurring disease, are called " human first killer ", the serious harm human health, and along with living condition's improvement, the sickness rate of this type disease is increasingly high.How effectively to prevent and treat this worldwide disease is the difficult problem of puzzlement medical circle always.
" the therapeutic angiogenesis " that medical circle proposes in recent years (being that medicine is put up a bridge) notion has been brought new hope for effectively preventing and treating coronary heart disease.Medicine is put up a bridge and is claimed the therapeutic angiogenesis again, promptly intervenes through some, promotes the cytokine or the receptor of ischemic myocardium angiogenic growth; Promote new little angiogenic growth; Foundation is the side Zhi Xunhuan of blood supply effectively, thereby obviously improves the ischemic myocardium blood supply, significantly reduces angina pectoris; The generation of cardiovascular danger incidents such as myocardial infarction, raising patient's quality of life.In this respect, Chinese medicine has remarkable advantages, not only can improve organismic internal environment, regulate, improve human body self-regeneration function, and expense is low, safe, convenient in application.Heart pill of Musk is documented in Chinese Pharmacopoeia 2010 editions, Moschus, Radix Ginseng extract, Calculus Bovis, Cortex Cinnamomi, Styrax, Venenum Bufonis and Borneolum Syntheticum totally 7 herbal medicines be prepared from.Have aromatic herbs activating YANG, the function that invigorates vital energy and reinforce the heart is used for angina pectoris, uncomfortable in chest and myocardial infarction that myocardial ischemia causes.The Heart pill of Musk research and development application is the history in existing more than 30 year so far, is one of common drug of preventing and treating coronary heart disease.Because of its curative effect is affirmed, safety economy, and have unique therapeutic angiogenesis effect, classified as national essential drugs.But discover that through us the curative effect of Heart pill of Musk is desirable not enough, if can develop the medicine that a kind of drug effect is superior to Heart pill of Musk, will bring glad tidings for more patients.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of pharmaceutical composition of treating coronary heart disease and preparation method thereof, to solve the dissatisfactory problem of drug effect of Heart pill of Musk.
For solving above technical problem; The present invention adopts following technical scheme: a kind of pharmaceutical composition of treating coronary heart disease; Said pharmaceutical composition calculates according to components by weight percent, is prepared from Moschus 1-15 part, Calculus Bovis 1-15 part, Radix Ginseng extract 10-50 part, Cortex Cinnamomi 10-50 part, Styrax 5-50 part, Borneolum Syntheticum 1-15 part, Venenum Bufonis 1-15 part 、 Eupolyphaga Seu Steleophaga 2-20 part and adjuvant.
Concrete; Said pharmaceutical composition calculates according to components by weight percent, is prepared from Moschus 2-10 part, Calculus Bovis 2-10 part, Radix Ginseng extract 20-40 part, Cortex Cinnamomi 20-40 part, Styrax 10-30 part, Borneolum Syntheticum 2-10 part, Venenum Bufonis 2-10 part 、 Eupolyphaga Seu Steleophaga 5-15 part and adjuvant.
More specifically, said pharmaceutical composition calculates according to components by weight percent, is prepared from 6 parts in Moschus, 6 parts of Calculus Boviss, 30 parts of Radix Ginseng extracts, 30 parts of Cortex Cinnamomis, 20 parts of Styrax, 6 parts of Borneolum Syntheticums, 10 parts of 6 parts of 、 Eupolyphaga Seu Steleophaga of Venenum Bufonis and adjuvant.
The preparation of drug combination method of said treatment coronary heart disease is: proportionally take by weighing Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis He Eupolyphaga Seu Steleophaga; Make up with acceptable pharmaceutic adjuvant in the medicine; And process according to the method for preparing of routine, process corresponding pharmaceutical preparation.
Concrete; The pharmaceutical composition of said treatment coronary heart disease prepares through following method: with Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Borneolum Syntheticum, Venenum Bufonis with Eupolyphaga Seu Steleophaga is ground into fine powder; Mix with Styrax and conventional adjuvant, process pharmaceutical preparation according to conventional method.
Concrete, the pharmaceutical composition of said treatment coronary heart disease prepares through following method: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, and each 2-6 hour, filter, filtrate recycling ethanol must Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, and each 0.5-3 hour, filter, filtrate recycling ethanol must Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 5-20 times of water gaging and extract 1-4 time, each 0.5-3 hour, filter, concentrate De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid, Borneolum Syntheticum dissolve with ethanol liquid and conventional adjuvant are mixed, process pharmaceutical preparation according to conventional method.
Said pharmaceutical preparation is meant any pharmaceutically useful dosage form.Specifically, said pharmaceutical preparation is selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, syrup, drop pill, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ejection preparation, freeze-dried powder, high-capacity injection, suppository, ointment, plaster, cream, spray and patch.
Preferably, said pharmaceutical preparation is tablet, capsule, granule, pill and oral liquid.
The method for preparing of pill according to the invention is: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis He Eupolyphaga Seu Steleophaga are total to Six-element are ground into fine powder altogether, Styrax adds the general ball of proper amount of white spirit, and drying promptly gets pill.
The method for preparing of capsule according to the invention is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, and each 2-6 hour, filter, filtrate recycling ethanol, drying is pulverized, and gets Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, and each 0.5-3 hour, filter, filtrate recycling ethanol, drying is pulverized, and gets Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 5-20 times of water gaging and extract 1-4 time, each 0.5-3 hour, filter, concentrate, drying is pulverized De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, add the dextrin of 10-30%, the starch of 5-10%, by equivalent multiplication method mix homogeneously; The HPMC solution system soft material that adds 2-4%; Granulate drying, granulate; Be sub-packed in the capsule shells, get capsule.
The method for preparing of tablet according to the invention is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, and each 2-6 hour, filter, filtrate recycling ethanol, drying is pulverized, and gets Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, and each 0.5-3 hour, filter, filtrate recycling ethanol, drying is pulverized, and gets Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 5-20 times of water gaging and extract 1-4 time, each 0.5-3 hour, filter, concentrate, drying is pulverized De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; Add the dextrin of 20%-40%, the magnesium stearate mixing of 0.2%-0.7%; Granulate; Tabletting promptly gets tablet.
The method for preparing of granule according to the invention is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, and each 2-6 hour, filter, filtrate recycling ethanol must Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, and each 0.5-3 hour, filter, filtrate recycling ethanol must Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 5-20 times of water gaging and extract 1-4 time, each 0.5-3 hour, filter, concentrate De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; The Icing Sugar mixing that adds 20-50%; Process granule, drying promptly gets granule.
The method for preparing of oral liquid according to the invention is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, and each 2-6 hour, filter, filtrate recycling ethanol must Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, and each 0.5-3 hour, filter, filtrate recycling ethanol must Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 5-20 times of water gaging and extract 1-4 time, each 0.5-3 hour, filter, concentrate De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, be dissolved in water, cold preservation 50-100 hour, filter; Other gets sucrose and adds and to make dissolving in the water boil evenly, filters, and processes simple syrup; Simple syrup added in the said medicine filtrating make final sugar content 10-40%, add the 0.1%-0.3% sodium benzoate, boil dissolving; Add water to full dose, transfer PH to 5-6, stir with sodium hydroxide; Filter, embedding promptly gets oral liquid.
Pharmaceutical preparation according to the invention is confirmed usage and dosage according to patient's situation in use.
Pharmaceutical composition according to the invention is when processing medicament, and the medicament of UD can contain pharmaceutically active substance 0.1-1000mg of the present invention, and all the other are acceptable accessories.Acceptable accessories can be the 0.1-99.9% of total formulation weight amount by weight.
Pharmaceutical composition according to the invention is on the basis of Heart pill of Musk prescription, increases the Eupolyphaga Seu Steleophaga prescription and gets.Show that after deliberation Eupolyphaga Seu Steleophaga is the strongest to the improvement effect of each parameter of hemorheological property: can reduce length, weight in wet base, the dry weight of external thrombus, shorten thrombelastogram, maximum setting time, reduce the platelet aggregation number; Improve platelet aggregation property; Reduce platelet adhesion reaction property, improve ED, speed erythrocyte electrophoresis speed; Improve erythrocyte aggregation, and can reduce fibrinogen content in the blood plasma.The present invention increases Eupolyphaga Seu Steleophaga on the basis of Heart pill of Musk prescription, can strengthen the blood coagulation resisting function in the medicine, has more obvious effects for the stickiness that improves blood.But Eupolyphaga Seu Steleophaga is slightly poisonous, and the heart sinus rate is slowed down, in addition in the Eupolyphaga Seu Steleophaga contained alkaloid the increase with dosage increases to the toxicity of heart.If the prescription consumption of Eupolyphaga Seu Steleophaga is too small, do not reach the purpose that increases drug effect, if the prescription consumption is excessive, can increase toxicity again to heart, therefore how to confirm the amount of Eupolyphaga Seu Steleophaga in prescription, be difficult point of the present invention.
In the pharmaceutical composition according to the invention, the Moschus blood circulation promoting and blood stasis dispelling, the pain relieving of having one's ideas straightened out is monarch drug.The ginseng qi-tonifying spleen invigorating; The pain relieving of having one's ideas straightened out of Cortex Cinnamomi warming YANG and promoting blood circulation, Venenum Bufonis, the Styrax aromatic herbs activating YANG is ministerial drug altogether; Artificial Calculus Bovis's refreshment of having one's ideas straightened out, Eupolyphaga Seu Steleophaga removing blood stasis with potent drugs blood, the Borneolum Syntheticum pain relieving of having one's ideas straightened out is adjuvant drug altogether.All medicines share, and play aromatic herbs activating YANG altogether, the pain relieving of having one's ideas straightened out, the merit that invigorates vital energy and reinforce the heart.Be used for angina pectoris, uncomfortable in chest, myocardial infarction that myocardial ischemia causes, also can be used for regeneration of coronary heart disease ischemic myocardium collateral blood vessels and medicine and put up a bridge.The applicant has carried out pharmacodynamics and anxious poison experiment to pharmaceutical preparation, and experimental result is following:
Experimental example 1: pharmacodynamic experiment research
1 material and method
1.1 experiment material
1.1.1 laboratory animal
100 of male SD rats, body weight (320 ± 20) g is provided by Shanghai Medical Univ's Experimental Animal Center.
1.1.2 experimental apparatus and medicine
Respirator model: Medical Instrument Factory affiliated to Zhejiang Univ manufacturing; IMS cell image analytical system; The Shen, Shanghai is risen information technology companies and is produced; Pentobarbital sodium: Shanghai chemical reagents corporation of Chinese Medicine group; Gentamicin injection liquid: Shanghai No.1 Bio-Chemical Pharmacetical Industry Co., Ltd; Factor rabbit source property polyclonal antibody: Denmark DAKO company; Bfgf-ESSEX: Yisheng Biological Pharmaceutical Co., Ltd., Shuhai; Heparin sodium injection: the biochemical thousand red pharmaceutical Co. Ltds in Chinese changzhou; Heart pill of Musk: Shanghai and xanthate industry; Pill of the present invention: according to the embodiment of the invention 1 said method preparation.
1.2 the foundation of animal model
1.2.1 animal modeling
Rat connects the artificial respirator assisted respiartion with ketalar (80mg/kg) intraperitoneal anesthesia after the tracheotomy.At left breast 4-5 rib catch cropping transverse incision, open the thoracic cavity from passivity separation between the 4th rib of left side, push the thoracic cavity gently; Expose heart; Cut off pericardium, descend the 1-2mm place with non-invasive suture ligation left side coronary artery, layer-by-layer suture thoracic wall then slightly at pulmonary conus and left auricle boundary; Open instant recording lead electrocardiogram behind the front, with the following cardiac muscle in ligation position bleach beat weaken and electrocardiogram occur the ST section back of a bow upwards obviously raise be modeling successfully.Modeling began the same day ip gentamycin pin 1 time every day (20,000 u/kg body weight), 3d altogether.
1.2.2 divide into groups and administration
Rat is divided into 6 groups: pill group of the present invention (1 group), Heart pill of Musk group (2 groups), multiple Ji and 3 groups of heparin coupling matched groups (}), model group (4 groups), Sham-operated control group (5 groups) and normal control group (6 groups), every group of 8-12 only, administration as follows respectively.1 group of pill 25mg/kg of the present invention that after the heart infarction modeling, begins to give every day, (add normal saline and process the 2mL suspension) ig continued for 8 weeks; 2 groups begin to give every day Heart pill of Musk 25mg/kg (add normal saline and process the 2mL suspension) ig, continued for 8 weeks after the heart infarction modeling; 3 groups are given bFGF sprinkling 1 immediately and lift (125AU), postoperative beginning sc heparin 1 time every day (1250u/kg), Sd altogether around ligation place after opening breast knot to prick arteria coronaria; 4 groups begin normal saline 2mL ig every day, 8 weeks after the heart infarction modeling totally.5 groups of not ligation arteria coronaria after opening breast are promptly sewed up thoracic wall and only wear 1 time at corresponding site with the atraumatic suture needle sky.Normally raise for 6 groups, do not have any intervention.8 weeks back execution animal is paid attention to dirty BIAO and BEN, 10% formalin fixed.
1.2.3 infarct size detects
Heart after fixing is through routine dehydration, transparent, FFPE, section, haematoxylin-Yihong (H-E) dyeing, and light microscopic is observed the myocardial necrosis situation down.Test at 10 times of object lens microscopicallies with IMS cytological image analyses system, detect myocardial infarction area and left chamber area respectively, infarct size (%) is represented with myocardial infarction area/left chamber area x 100%.
1.2.4 infraction marginal zone myocardial vascular surface density detects
Section behind cardiac muscular tissue's factor immunohistochemical staining; Through IMS cytological image analyses system handles; Measuring left ventricular infraction marginal zone shows the number of blood vessel of factor positive staining; Mean is got in every section 5 visuals field of random observation (x 100), and can calculate every square millimeter number of blood vessel according to the measurement window area again is surface density.
1.3 detection index
Infarct size, blood vessel surface density.
2 results
2.1 modeling and animal dead situation
Test shared 100 male SD rats that go.Get wherein 82 rats and cause the heart infarction model, in the operation 24h dead 34,48 of survival are divided into pill group of the present invention, Heart pill of Musk group, positive drug matched group (Bfgf-ESSEX adds heparin) and negative medicine matched group, every group respectively 12.8 of normal group are all not dead with 10 rats of sham operated rats.In the feeding process, each dead 1 of low dose of, heavy dose of Heart pill of Musk positive controls and model group.
2.2 infarct size relatively
Mirror finds that down sham operated rats and normal control group also have few part myocardial necrosis.After cervical vertebra dislocation method execution rat is opened the thoracic cavity; All rat hearts are all being beated; Therefore the myocardial infarction of considering sham operated rats and normal rats small size possibly can cause the part myocardial necrosis relevant with the anaerobic condition of dead rat behind the execution rat; The infarction of this fraction is the striped muscle fracture, and the infarction of 4 heart infarction rat groups all has fibrosis.
Each organizes testing result, and (x ± s) expression compares each group difference with the multiple comparisons variance analysis, adopts SPSS 10.0 softwares to add up with mean standard deviation.The result sees table 1
The influence of table 1 pair rat heart muscle infarct size
Can find out that from table 1 infarct size of model group is maximum, with the infarct size of sham operated rats and normal group the difference of highly significant arranged, P＜0.01 explains that the heart infarction modeling is successful.Though sham operated rats is bigger slightly than the infarct size of normal group, difference does not have significance, and P＞0.05 explains out that breast itself is little to the infarct size influence.1 group, 2 groups of medication and 3 groups and model group are than all significantly reducing infarct size.Heart pill of Musk group infarct size does not have remarkable statistical significance with positive controls than difference, and P＞0.05 explains that the effect of Heart pill of Musk reduction infarct size and positive control medicine is similar; The infarct size of pill group of the present invention and positive controls ratio, difference has significance, P＜0.05; Compare with the Heart pill of Musk group; Difference also has significance, and P＜0.05 explains that pill group of the present invention is better than Bfgf-ESSEX in effect aspect the minimizing infarct size and adds heparin group and Heart pill of Musk group.
2.3 infarction marginal zone blood vessel surface density relatively
Each organizes testing result, and (x ± s) expression compares each group difference with the multiple comparisons variance analysis, adopts SPSS 10.0 softwares to add up, and the result sees table 2 with mean standard deviation.
The influence of table 2 pair rat heart muscle infarction marginal zone blood vessel surface density
Can be found out that by table 2 the blood vessel surface density of model group is higher than sham operated rats and normal group, difference has statistical significance, P＜0.05.The angiogenesis that compensatory takes place behind the heart infarction is described.And sham operated rats does not have significance with normal group than difference, and P＞0.05 explains that operation itself influences not quite the result.1 group, 2 groups of medication and 3 groups and model group are than remarkable angiogenesis effect, P＜0.01 are all arranged.Pill group of the present invention is compared with positive control medicine group, the difference not statistically signigicant of blood vessel surface density, P＞0.05; Pill group of the present invention is compared with the blood vessel surface density of Heart pill of Musk group, P＜0.05, and significant difference explains that pill group of the present invention is in group.
3 discuss
Can know that according to experimental result medicine of the present invention is being superior to Heart pill of Musk aspect minimizing rat heart muscle infarct size and the angiogenesis promoting effect.
Experimental example 2: acute toxicity testing research
1, according to each medicament composing prescription in the table 3, is prepared into pill according to the method for the invention.
Table 3
2, give said medicine for the disposable filling stomach of mice, observed 14 days, survey its LD
50, the result sees table 4:
Table 4
Can know that according to above-mentioned experimental result along with the increasing of Eupolyphaga Seu Steleophaga dosage, drug toxicity increases, and considers the medicinal effects of medicine, selecting the prescription of medicine 4 is best prescription.
Beneficial effect of the present invention: compared with prior art; Medicine according to the invention can have aromatic herbs activating YANG, the pain relieving of having one's ideas straightened out, the effect that invigorates vital energy and reinforce the heart; Be used for angina pectoris, uncomfortable in chest and myocardial infarction that myocardial ischemia causes, also can be used for regeneration of coronary heart disease ischemic myocardium collateral blood vessels and medicine and put up a bridge.Medicine according to the invention and Heart pill of Musk compare, and drug effect obviously increases, and has reached goal of the invention.
The specific embodiment:
Embodiment 1
Prescription: Moschus 6g, Calculus Bovis 6g, Radix Ginseng extract 30g, Cortex Cinnamomi 30g, Styrax 20g, Borneolum Syntheticum 6g, Venenum Bufonis 6g 、 Eupolyphaga Seu Steleophaga 10g
Preparation technology is: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis He Eupolyphaga Seu Steleophaga are total to Six-element are ground into fine powder altogether, Styrax adds the general ball of proper amount of white spirit, and drying promptly gets pill.
Usage and dosage: oral, one time 1～2 ball, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 2
Prescription: Moschus 15g, Calculus Bovis 15g, Radix Ginseng extract 50g, Cortex Cinnamomi 50g, Styrax 50g, Borneolum Syntheticum 15g, Venenum Bufonis 15g 、 Eupolyphaga Seu Steleophaga 20g
Preparation technology is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, with the alcohol reflux of 5 times of amounts 60% 3 times, and each 2 hours, filter, filtrate recycling ethanol, drying is pulverized, and gets Moschus extract; Venenum Bufonis is pulverized, with the alcohol reflux of 30 times of amounts 60% 3 times, and each 0.5 hour, filter, filtrate recycling ethanol, drying is pulverized, and gets Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 5 times of water gagings and extract 4 times, each 0.5 hour, filter, concentrate, drying is pulverized De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 8 times of water gagings, extracts 1 hour with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, add 20% dextrin, 5% starch, by equivalent multiplication method mix homogeneously; The HPMC solution system soft material of adding 3%; Granulate drying, granulate; Be sub-packed in the capsule shells, get capsule.
Usage and dosage: oral, one time 3,3 times on the one; Or take during paresthesia epilepsy.
Embodiment 3
Prescription: Moschus 1g, Calculus Bovis 1g, Radix Ginseng extract 10g, Cortex Cinnamomi 10g, Styrax 5g, Borneolum Syntheticum 1g, Venenum Bufonis 1g 、 Eupolyphaga Seu Steleophaga 2g
Preparation technology is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, with the alcohol reflux of 10 times of amounts 85% 2 times, and each 3 hours, filter, filtrate recycling ethanol must Moschus extract; Venenum Bufonis is pulverized, and with the alcohol reflux of 100 times of amounts 95% 3 hours, filters, and filtrate recycling ethanol must Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 10 times of water gagings and extract 4 times, each 2 hours, filter, concentrate De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 9 times of water gagings, extracts 0.5 hour with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; The Icing Sugar mixing of adding 40%; Process granule, drying promptly gets granule.
Usage and dosage: oral, a 5g, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 4
Prescription: Moschus 15g, Calculus Bovis 1g, Radix Ginseng extract 10g, Cortex Cinnamomi 50g, Styrax 50g, Borneolum Syntheticum 1g, Venenum Bufonis 1g 、 Eupolyphaga Seu Steleophaga 20g
Preparation technology is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, with the alcohol reflux of 15 times of amounts 70% 13 times, and each 16 hours, filter, filtrate recycling ethanol must Moschus extract; Venenum Bufonis is pulverized, with the alcohol reflux of 30 times of amounts 60% 3 times, and each 1 hour, filter, filtrate recycling ethanol must Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 15 times of water gagings and extract 3 times, each 1 hour, filter, concentrate De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 10 times of water gagings, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, be dissolved in water, cold preservation 72 hours filters; Other gets sucrose and adds and to make dissolving in the water boil evenly, filters, and processes simple syrup; Simple syrup added in the said medicine filtrating make final sugar content 20%, add 0.2% sodium benzoate, boil dissolving; Add water to 100ml, transfer PH to 5-6, stir with sodium hydroxide; Filter, embedding promptly gets oral liquid.
Usage and dosage: oral, a 5ml, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 5
Prescription: Moschus 10g, Calculus Bovis 10g, Radix Ginseng extract 40g, Cortex Cinnamomi 40g, Styrax 30g, Borneolum Syntheticum 10g, Venenum Bufonis 10g 、 Eupolyphaga Seu Steleophaga 15g
Preparation technology is: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis He Eupolyphaga Seu Steleophaga are total to Six-element are ground into fine powder altogether, Styrax adds the general ball of proper amount of white spirit, and drying promptly gets pill.
Usage and dosage: oral, one time 1～2 ball, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 6
Prescription: Moschus 2g, Calculus Bovis 2g, Radix Ginseng extract 20g, Cortex Cinnamomi 20g, Styrax 10g, Borneolum Syntheticum 2g, Venenum Bufonis 2g 、 Eupolyphaga Seu Steleophaga 5g
Preparation technology is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, with the alcohol reflux of 8 times of amounts 80% 3 times, and each 5 hours, filter, filtrate recycling ethanol must Moschus extract; Venenum Bufonis is pulverized, with the alcohol reflux of 70 times of amounts 70% 2 times, and each 2 hours, filter, filtrate recycling ethanol must Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 12 times of water gagings and extract 2 times, each 1 hour, filter, concentrate De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 10 times of water gagings, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, be dissolved in water, cold preservation 50 hours filters; Other gets sucrose and adds and to make dissolving in the water boil evenly, filters, and processes simple syrup, simple syrup is added in the said medicine filtrating make final sugar content 10%; Add 0.1% sodium benzoate, boil dissolving, add water to 100ml, transfer PH to 5-6 with sodium hydroxide; Stir, filter, embedding promptly gets oral liquid.
Usage and dosage: oral, a 5-10ml, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 7
Prescription: Moschus 2g, Calculus Bovis 10g, Radix Ginseng extract 40g, Cortex Cinnamomi 20g, Styrax 10g, Borneolum Syntheticum 10g, Venenum Bufonis 10g 、 Eupolyphaga Seu Steleophaga 5g
Preparation technology is: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, with the alcohol reflux of 20 times of amounts 90% 3 times, and each 2 hours, filter, filtrate recycling ethanol, drying is pulverized, and gets Moschus extract; Venenum Bufonis is pulverized, with the alcohol reflux of 100 times of amounts 95% 3 hours, filters, and filtrate recycling ethanol, drying is pulverized, and gets Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decocts with 20 times of water gagings and extracts 3 hours, filters, and concentrates, and drying is pulverized De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 10 times of water gagings, extracts 3 hours with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; Add 30% dextrin, 0.5% magnesium stearate mixing; Granulate, tabletting promptly gets tablet.
Usage and dosage: oral, one time 3,3 times on the one; Or take during paresthesia epilepsy.
Claims (9)
1. pharmaceutical composition of treating coronary heart disease; It is characterized in that: said pharmaceutical composition calculates according to components by weight percent, is prepared from Moschus 1-15 part, Calculus Bovis 1-15 part, Radix Ginseng extract 10-50 part, Cortex Cinnamomi 10-50 part, Styrax 5-50 part, Borneolum Syntheticum 1-15 part, Venenum Bufonis 1-15 part 、 Eupolyphaga Seu Steleophaga 2-20 part and adjuvant.
2. according to the pharmaceutical composition of the said treatment coronary heart disease of claim 1; It is characterized in that: said pharmaceutical composition calculates according to components by weight percent, is prepared from Moschus 2-10 part, Calculus Bovis 2-10 part, Radix Ginseng extract 20-40 part, Cortex Cinnamomi 20-40 part, Styrax 10-30 part, Borneolum Syntheticum 2-10 part, Venenum Bufonis 2-10 part 、 Eupolyphaga Seu Steleophaga 5-15 part and adjuvant.
3. according to the pharmaceutical composition of the said treatment coronary heart disease of claim 1; It is characterized in that: said pharmaceutical composition calculates according to components by weight percent, is prepared from 6 parts in Moschus, 6 parts of Calculus Boviss, 30 parts of Radix Ginseng extracts, 30 parts of Cortex Cinnamomis, 20 parts of Styrax, 6 parts of Borneolum Syntheticums, 10 parts of 6 parts of 、 Eupolyphaga Seu Steleophaga of Venenum Bufonis and adjuvant.
4. the method for preparing the pharmaceutical composition of each said treatment coronary heart disease among the claim 1-3; It is characterized in that: proportionally take by weighing Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis He Eupolyphaga Seu Steleophaga; Make up with acceptable pharmaceutic adjuvant in the medicine; And process according to the method for preparing of routine, process corresponding pharmaceutical preparation.
5. according to the said method of claim 4; It is characterized in that: the pharmaceutical composition of said treatment coronary heart disease prepares through following method: with Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Borneolum Syntheticum, Venenum Bufonis with Eupolyphaga Seu Steleophaga is ground into fine powder; Mix with Styrax and conventional adjuvant, process pharmaceutical preparation according to conventional method.
6. according to the said method of claim 4, it is characterized in that: the pharmaceutical composition of said treatment coronary heart disease prepares through following method: Calculus Bovis, Radix Ginseng extract pulverize separately become fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, and each 2-6 hour, filter, filtrate recycling ethanol must Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, and each 0.5-3 hour, filter, filtrate recycling ethanol must Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and decoct with 5-20 times of water gaging and extract 1-4 time, each 0.5-3 hour, filter, concentrate De Eupolyphaga Seu Steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, extracts volatile oil with hydrodistillation, gets Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used dissolve with ethanol respectively; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract 、 Eupolyphaga Seu Steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid, Borneolum Syntheticum dissolve with ethanol liquid and conventional adjuvant are mixed, process pharmaceutical preparation according to conventional method.
7. according to the said method of claim 4, it is characterized in that: said pharmaceutical preparation is meant any pharmaceutically useful dosage form.
8. according to the said method of claim 7, it is characterized in that: said pharmaceutical preparation is selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, syrup, drop pill, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ejection preparation, freeze-dried powder, high-capacity injection, suppository, ointment, plaster, cream, spray and patch.
9. said according to Claim 8 method is characterized in that: said pharmaceutical preparation is tablet, capsule, granule, pill and oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110247040.2A CN102526195B (en) | 2011-08-24 | 2011-08-24 | Medicinal composition for treating coronary disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110247040.2A CN102526195B (en) | 2011-08-24 | 2011-08-24 | Medicinal composition for treating coronary disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526195A true CN102526195A (en) | 2012-07-04 |
| CN102526195B CN102526195B (en) | 2014-03-26 |
Family
ID=46335016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110247040.2A Active CN102526195B (en) | 2011-08-24 | 2011-08-24 | Medicinal composition for treating coronary disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526195B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435114A (en) * | 2014-03-28 | 2015-03-25 | 上海和黄药业有限公司 | Method for preparing cardiovascular disease drug micropills |
| CN107669738A (en) * | 2017-10-18 | 2018-02-09 | 广东大鹏医药科技有限公司 | A kind of promoting blood circulation and removing blood stasis, Chinese medicine preparation for invigorating vital energy and reinforce the heart and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225203A (en) * | 1987-07-01 | 1993-07-06 | Kim Young S | Pharmaceutical liquid composition containing Bezoar bovis |
| CN1557426A (en) * | 2004-02-11 | 2004-12-29 | 冯学君 | Preparation of moschus for refreshment |
| CN1839940A (en) * | 2006-01-05 | 2006-10-04 | 高成富 | Musk formulation for protecting heart and its preparation method |
| KR20090016525A (en) * | 2007-08-11 | 2009-02-16 | 김덕희 | Candy has medical stuff |
| CN101549014A (en) * | 2008-04-02 | 2009-10-07 | 北京卓越同创药物研究院 | Heart-protecting musk oral preparation and preparation method thereof |
-
2011
- 2011-08-24 CN CN201110247040.2A patent/CN102526195B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225203A (en) * | 1987-07-01 | 1993-07-06 | Kim Young S | Pharmaceutical liquid composition containing Bezoar bovis |
| US5225203C1 (en) * | 1987-07-01 | 2001-05-15 | Kim Won Kyq Son | Pharmaceutical liquid composition containing bezoar bovis |
| CN1557426A (en) * | 2004-02-11 | 2004-12-29 | 冯学君 | Preparation of moschus for refreshment |
| CN1839940A (en) * | 2006-01-05 | 2006-10-04 | 高成富 | Musk formulation for protecting heart and its preparation method |
| KR20090016525A (en) * | 2007-08-11 | 2009-02-16 | 김덕희 | Candy has medical stuff |
| CN101549014A (en) * | 2008-04-02 | 2009-10-07 | 北京卓越同创药物研究院 | Heart-protecting musk oral preparation and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435114A (en) * | 2014-03-28 | 2015-03-25 | 上海和黄药业有限公司 | Method for preparing cardiovascular disease drug micropills |
| CN104435114B (en) * | 2014-03-28 | 2018-04-13 | 上海和黄药业有限公司 | A kind of preparation method of cardiovascular disease medicine particulate ball |
| CN107669738A (en) * | 2017-10-18 | 2018-02-09 | 广东大鹏医药科技有限公司 | A kind of promoting blood circulation and removing blood stasis, Chinese medicine preparation for invigorating vital energy and reinforce the heart and preparation method thereof |
| CN107669738B (en) * | 2017-10-18 | 2020-10-16 | 广东大鹏医药科技有限公司 | Traditional Chinese medicine preparation for promoting blood circulation to remove blood stasis, tonifying qi and strengthening heart and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526195B (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112245552B (en) | Traditional Chinese medicine preparation with anti-atherosclerosis effect, preparation method and application | |
| CN106138210A (en) | Butterflybush flower and the application of the medicine as preparation treatment hypertensive cardiopathy for the extract thereof | |
| CN101549014A (en) | Heart-protecting musk oral preparation and preparation method thereof | |
| CN102526195B (en) | Medicinal composition for treating coronary disease and preparation method thereof | |
| CN102085257A (en) | Preparation method of micro-pills prepared from cassia twig and tuckahoe | |
| CN104083553B (en) | For preventing or treating the Chinese medicine extract of coronary heart disease, compositions and its production and use | |
| CN107744571B (en) | Pharmaceutical composition for improving vascular endothelial dysfunction and preparation method and application thereof | |
| CN105267867A (en) | Application of traditional Chinese medicine to preparation of medicine for eliminating heart toxic and side effects of antitumor medicine or preparation of medicine with synergic antitumor effect with adriamycin | |
| CN102309632B (en) | Application of pharmaceutical composition in preparation of pharmaceuticals for treating complications of diabetes | |
| CN107982484A (en) | Treat Chinese medicinal compound extract of diabetic retinopathy and its preparation method and application | |
| CN101843763B (en) | Traditional Chinese medicine capable of treating complicated symptom of diabetes and stagnant heat and application thereof | |
| CN111544473A (en) | Refined coronary heart disease granule extraction preparation process for treating coronary heart disease and angina pectoris, traditional Chinese medicine and extract thereof | |
| CN100430072C (en) | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases | |
| CN101176751B (en) | Pharmaceutical composition of red sage root and cassia twig | |
| CN1718191A (en) | Total secondary ginseng glucoside oral disintegration tablets prepn. method and application thereof | |
| CN104510884A (en) | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN102670785B (en) | Preparation method of conventional Chinese medicine composition for treating primary hypertension | |
| CN101161268B (en) | Pharmaceutical composition of red sage root and cattail pollen | |
| CN1872147A (en) | Dispersion tablet of red sage root for coronary artery and preparation method | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin | |
| CN105395650A (en) | Applications of Shu Gan Ning preparation in preparation of medicines treating osteoporosis and complications of the osteoporosis | |
| CN115429836A (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN105267632A (en) | Traditional Chinese medicine composition composition treating diabetic macular edema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180601 Address after: No. 1, Beijing Road, Yunyan District, Guizhou Province, Guizhou Patentee after: Guizhou Shenqi Drug Research Institute Address before: No. 1 Beijing Road, Guiyang, Guizhou Patentee before: Guizhou Maojka Group Holding Co., Ltd. |
|
| TR01 | Transfer of patent right |